Details
| Stereochemistry | MIXED |
| Molecular Formula | C17H24O3 |
| Molecular Weight | 276.3707 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC(CC(C)(C)C1)OC(=O)C(O)C2=CC=CC=C2
InChI
InChIKey=WZHCOOQXZCIUNC-UHFFFAOYSA-N
InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
| Molecular Formula | C17H24O3 |
| Molecular Weight | 276.3707 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cyclandelate is a vasodilator developed for the treatment of cardiovascular diseases. The drug was used in many countries for such diseases as intermittent claudication, arteriosclerosis obliterans, thrombophlebitis, nocturnal leg cramps, local frostbite, Raynaud's phenomenon. In the USA it was also approved for intermittent claudication and cognitive dysfunction in Alzheimer's disease under the name Cyclospasmol. Cyclandelate exerts its effect by blocking calcium channels and inhibiting smooth muscles contration. Cyclandelate was withdrawn from the market in the USA for lack of effectiveness.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2363032 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CYCLOSPASMOL Approved UseA treatment for intermittent claudication and a treatment for cognitive
dysfunction in Alzheimer's disease. |
|||
| Palliative | CYCLOSPASMOL Approved UseA treatment for intermittent claudication and a treatment for cognitive
dysfunction in Alzheimer's disease. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. | 2010-09-29 |
|
| Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
| Anthroposophic therapy for migraine: a two-year prospective cohort study in routine outpatient settings. | 2010 |
|
| Optimizing prophylactic treatment of migraine: Subtypes and patient matching. | 2008-10 |
|
| Metabolism of ciclesonide in the upper and lower airways: review of available data. | 2008-09-07 |
|
| Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite. | 2007-10 |
|
| Vasospastic amaurosis fugax. | 2003-02 |
|
| Chiral separation of several drugs using electrophoresis with dual cyclodextrin systems. | 2002-09 |
|
| Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. | 2001-05 |
|
| Cyclandelate in the prophylaxis of migraine: a placebo-controlled study. | 2001-02 |
|
| Quinine blindness. | 1992-12 |
|
| Screening for new compounds with antiherpes activity. | 1984-10 |
Patents
Sample Use Guides
The usual dose of cyclandelaye is between 400 - 800 mg per day, given in two or four divided doses. If indicated, higher doses of 1200 mg to 1600 mg per day may be given in four divided doses before meals and at bedtime, for two to four weeks, and then reduced by 200 mg decrements to the usual dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3622308
Cyclandelate in concentrations between 10 and 50 uM induced a dose-dependent increase in the basal level of cytosolic Ca++ of unstimulated platelets. In platelets stimulated with thrombin (5 U/ml) or platelet activating factor (1 uM), cyclandelate strongly inhibited the increase of cystolic Ca++ in the presence of extracellular Ca++, but in the absence of extracellular Ca++ only a weak inhibition was observed. This inhibition was dose dependent and optimal at about 50 uM, the concentration at which Ca++ mobilisation was suppressed to about 10% of control values, and at which cyclandelate inhibits platelet aggregation.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:26:40 GMT 2025
by
admin
on
Mon Mar 31 23:26:40 GMT 2025
|
| Record UNII |
4139O1OAY2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29707
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
||
|
LIVERTOX |
245
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
||
|
WHO-VATC |
QC04AX01
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
||
|
WHO-ATC |
C04AX01
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
456-59-7
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
4139O1OAY2
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
CYCLANDELATE
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
1152701
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
100000092568
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
SUB06841MIG
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
2893
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
3988
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
DTXSID4022862
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
D003495
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
2970
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB04838
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
747
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
3046
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
207-271-6
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
CHEMBL1480987
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
758910
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
821
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
C77072
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | |||
|
m3967
Created by
admin on Mon Mar 31 23:26:40 GMT 2025 , Edited by admin on Mon Mar 31 23:26:40 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |